HER-2/neu gene amplification by Fluorescence In Situ Hybridization allows risk-group assessment in node-negative breast cancer

International Journal of Oncology

Volumn 14, Issue 4, 1999, Pages 663-671

  Harbeck, Nadia ^a,d   Ross, Jeffrey S ^c   Yurdseven, Suna ^a   Dettmar, Peer ^a   Pölcher, Martin ^a   Kuhn, Walther ^a   Ulm, Kurt ^b   Graeff, Henner ^a   Schmitt, Manfred ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c ALBANY MEDICAL COLLEGE   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

FISH; Gene amplification; HER 2 neu; Node negative breast cancer; PAI 1; Prognosis; Protein ovcrcxpression; Proto oncogene c erbB 2; uPA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RISK ASSESSMENT; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033109529     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.14.4.663     Document Type: Article

References (52)

1. Clark GM and McGuire W: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15: 20-25, 1988.
2. McGuire W and Clark GM: Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 326: 1756-1761, 1992.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
4. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM and Richards MA: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 63: 444-446, 1991.
5. Lupu R, Cardillo M, Harris L, Hijazi M and Rosenberg K: Interaction between erbB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol 6: 135-145, 1995.
6. Slamon DJ and Clark GM: Amplification of C-ERB-B2 and aggressive breast tumors? Science 240: 1795-1798, 1988.
7. De Potter CR: The neu oncogene: more than a prognostic indicator? Hum Pathol 25: 1264-1268, 1994.
8. Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA and Preisler H: C-myc, c-erb-B2, and Ki-67 expression in normal breast tissue and in invasive and non-invasive breast carcinoma. Cancer Res 52: 2597-2602, 1992.
9. Kalogeraki A, Tzardi M, Datseris G, Kanavaros P, Karvelas C, Chaliadakis G, Tsiftsis D and Delides G: C-erbB-2: expression in patients with breast carcinoma in comparison to patients with benign breast diseases. Anticancer Res 16: 765-772, 1996.
10. Revillon F, Bonneterre J and Peyrat JP: Review: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34: 791-808, 1998.
11. Ross JS and Fletcher JA: The Her-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Oncologist 3: 237-252, 1998.
12. Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, Slamon DJ, Phillips RN, Ross JS, Wolman SR and Flom KJ: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997.
13. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KPH, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W and McCready D for the Toronto Breast Cancer Study Group: Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol 16: 1340-1349, 1998.
14. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L and Cooperating Investigators: Her-2/neu node-negative breast cancer. Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992.
15. Klijn JGM, Berns EMJJ, Bontenbal M and Foekens J: Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19: 45-63, 1993.
16. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M and Henderson IC: C-erbR-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260-1266, 1994.
17. Carlomagno C, Perrone F, Gallo C, De Laurentiis M, Lauria R, Morabito A, Pettinato G, Panico L, D'Antonio A, Bianco AR and De Placido S: c-erbB-2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14: 2702-2708, 1996.
18. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK and Allred DC: Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3: 593-600, 1997.
19. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JN and Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 50: 6827-6829, 1990.
20. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H and Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong, independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24: 195-208, 1993.
21. Grøhndahl-Hansen J, Christensen IJ, Rosenquist C, Brünner N, Mouridsen HT, Danø K and Blichert-Toft M: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521, 1993.
22. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A and Oglobine J: Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 69: 398-405, 1994.
23. Foekens JA, Schmitt M, van Putten WLJ, Peters HA, Kramer MD, Jänicke F and Klijn JGM: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12: 1648-1658, 1994.
24. Fernö M, Bendahl PO, Borg A, Brundell J, Hirschberg L, Olsson H and Killander D: Urokinase plasminogen activator, a strong independent prognostic factor in breast cancer, analysed in steroid receptor cytosols with a luminometric immunoassay. Eur J Cancer 32A: 793-801, 1996.
25. Knoop A, Andreasen PA, Andersen JA, Hansen S, Laenkholm AV, Simonsen ACW, Andersen J, Overgaard J and Rose C: Prognostic significance of urokinase-type plasminogen activator and plasminosen activator inhibitor-1 in primary breast cancer. Br J Cancer 77: 932-940, 1998.
26. Kute TE, Grøhndahl-Hansen J, Shao SM, Long R, Russell G and Brünner N: Low cathepsin D and low plasminogen activator type 1 inhibitor in tumor cytosols defines a group of node negative breast cancer patients with low risk of recurrence. Breast Cancer Res Treat 47: 9-16, 1998.
27. Harbeck N, Dettmar P, Thomssen C, Berger U, Ulm K, Kates R, Jänicke F, Höfler H, Graeff H and Schmitt M: Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: six-year median follow-up. Br J Cancer (In press).
28. Blankenstein MA: Biochemical assessment of tissue prognostic factors in breast cancer. Breast 6: 31-37, 1997.
29. Jänicke F, Thomssen C, Pache L, Schmitt M and Graeff H: Urokinase (uPA) and PAI-1 as selection criteria for adjuvant chemotherapy in axillary node-negative breast cancer patients. In: Prospects in Diagnosis and Treatment of Cancer. Schmitt M, Graeff H and Jänicke F (eds). Elsevier Science, pp207-218, 1994.
30. Harbeck N, Dettmar P, Thomssen C, Henselmann B, Kuhn W, Ulm K, Jänicke F, Höfler H, Graeff H and Schmitt M: Prognostic impact of tumor biological factors on survival in node-negative breast cancer. Anticancer Res 18: 2187-2198, 1998.
31. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W and Graeff H: Urokinase-type plasminogen activator (uPA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78, 1990.
32. Jänicke F, Pache L, Schmitt M, Ulm K, Thomssen C, Prechtl A and Graeff H: Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Cancer Res 54: 2527-2530, 1994.
33. Schmitt M, Thomssen C, Ulm K, Seiderer A, Harbeck N, Höfler H, Jänicke F and Graeff H: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76: 306-311, 1997.
34. Kaplan EL and Meier P: Non-parametric estimation from incomplete observations. J Am Statist Assoc 53: 457-481, 1958.
35. Cox DR: Regression models and life-tables. J R Statist Soc (B) 34: 187-200, 1972.
36. Breiman I, Friedman J, Olshen R and Stone C: Classification and regression trees. Chapman and Hall, New York, 1984.
37. Clark G: Prognostic and predictive factors. In: Diseases of the Breast. Harris JR, Lippmann ME, Morrow M and Hellmann S (eds). Lippincott-Raven Publishers, Philadelphia, pp461-485, 1996.
38. Jacobs TW, Prioleau JE, Stillman IE and Schnitt SJ: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88: 1054-1059, 1996.
39. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J. Birnbaum D and Jacquemier J: Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 173: 65-75, 1994.
40. Busmanis I, Feleppa F, Jones A, McGrath KM, Reed R, Collins J, Russell I and Begley CG: Analysis of cerbB2 expression using a panel of six commercially available antibodies. Pathology 26: 261-267, 1994.
41. Press MF, Hung G, Godolphin W and Slamon DJ: Sensitivity of HER-2/neu antibodies in archival samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54: 2771-2777, 1994.
42. Van Diest PJ, van Dam P, Henzen-Logmans SC, Berns E, van der Burg ME, Green J and Vergote I: A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer Gynaecological Cancer Cooperative Group. J Clin Pathol 50: 801-804, 1997.
43. Dittadi R, Brazzale A, Pappagallo G, Salbe C, Nascimben O, Rosabian A and Gion M: ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 17: 1245-1247, 1997.
44. Eissa S, Khalifa A, El-Gharib A, Salah N and Mohamed MK: Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res 17: 3091-3097, 1997.
45. Liu G, Shuman MA and Cohen RL: Co-expression of urokinase, urokinase-receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int J Cancer 60: 501-506, 1995.
46. Andreasen PA, Kjöller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72: 1-22, 1997.
47. Bajou K, Noel A, Gerard RD, Massen V, Brunner N, Holst-Hansen C, Skobe M, Fusening NE, Carmeliet P, Collen D and Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4: 923-928, 1998.
48. Danø K, Andreasen PA, Grøhndahl-Hansen J, Kristensen P, Nielsen L and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res 44: 139-266, 1985.
49. Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F and Graeff H: Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 78: 285-296, 1997.
50. Lauffenburger D: Making connections count. Nature 383: 390-391, 1996.
51. 3 binding to vitronectin. Nature 383: 441-443, 1996.
52. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV and Chapman HA: Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555, 1996.